A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Contact:
NCT Number:
Protocol:
AAAT2009
Study Status:
Closed to Accrual, Study Active
Population:
Adult
Phase:
II
This study is being done to answer the following question: Is the combination of the drugs belinostat and SGI-110 (guadecitabine) effective at lowering the chance of your chondrosarcoma growing or spreading?
Are you Eligible? (Inclusion Criteria)
- Have you been diagnosed with chondrosarcoma that cannot be removed by
- surgery?
- Are you 18 years of age or older?
- Are you able to come to the clinic for 5 consecutive days each month to get
- treatment?
Specialty Area(s)
Sarcomas (Bone and Soft Tissue)
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
